diagnost tool
diagnost tool
price close busi april
aet acla lawsuit key swing factor
labcorp report result open th
wed respect believ pois benefit tax reform well
posit consolid larg highli fragment larg ineffici lab
market think help lh off-set pama reimburs cut
flag caution impact sever weather may
lab busi impact logist transport specimen around
 heavi snowfal easter coastal flood pound northeast
significantli vs boston saw worst coastal flood year sinc
blizzard mani us boston lost power day
result estim weather impact compani laboratori
busi expect impact bit lh think weather
impact lh covanc chiltern busi minim
rational weather impact base check region storm track
websit greater boston area got snow y/i
day cancel school y/i minneapolis/st paul got
snow y/i even got anoth april hit mid-west
hard last weekend tornado touch nc week thu even could see
weather impact versu prior year make estim chang
lower estim estim revenue volum impact
see figur result sever weather lower revenue
estim y/i lower adj ep estim
take adj ep
consensu rev adj ep look total
volum rev/req model gm y/
om y/i prior result
haircut lower adj ep low end
preview lh estim revenue volum impact lh dx busi
exclud drug develop result sever weather lower
revenue estim y/i lower
adj ep estim take adj ep estim
consensu rev adj ep result
haircut lower adj ep
midpoint lh ep guid
contract recent host investor meet quest indic
remain activ dialogu larg lab contract exclus
lh end think wall street price statu quo howev
think possibl contract open lab provid
view would add upsid even contact aet similarli open lh
acla recent file repli support motion summari judgment acla vs
hh think statu quo base case relief bull
case acla get wish hospit outreach lab becom applic lab
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
acla lawsuit key swing factor
labcorp report result open th
wed respect believ pois benefit tax reform
well posit consolid larg highli fragment larg ineffici
lab market think help lh off-set pama reimburs cut
flag caution impact sever weather may
lab busi impact logist transport specimen around
 heavi snowfal easter coastal flood pound northeast
significantli vs boston saw worst coastal flood year
sinc blizzard mani us boston lost power day
result estim weather impact compani
laboratori busi expect impact bit lh think
weather impact lh covanc chiltern busi minim
rational weather impact base check region storm track
websit greater boston area got snow y/i
day cancel school y/i minneapolis/st paul
got snow y/i even got anoth april hit
mid-west hard last weekend tornado touch nc week thu
even could see weather impact versu prior year
figur boston believ overal snowfal one import variabl captur weather sever snow y/i
hill observatori scienc center milton
figur minneapoli st paul minnesota snow increas y/i lighter season last year
depart natur state minnesota
diagnost tool
lower estim estim revenu volum impact
see figur result sever weather lower
revenue estim y/i lower adj ep
estim take adj ep
consensu rev adj ep
look total volum rev/req model
gm y/i om y/i prior
result haircut lower adj ep
low end guid
figur winter averag ep headwind relat advers weather
preview lh estim revenue volum impact lh lab busi
exclud drug develop result sever weather result
lower revenue estim y/i
lower adj ep estim take
adj ep estim consensu rev
adj ep result haircut lower adj ep
midpoint lh ep guid
contract recent host investor meet
indic remain activ dialogu larg lab contract
exclus lh end think wall street price statu
quo howev think probabl contract open
lab provid view would add upsid even contact
aet similarli open lh sinc cover live aet
remind alreadi book busi howev
quantifi size busi
acla recent file repli support motion summari judgment acla vs
hh think statu quo base case relief bull
case inclus hospit outreach lab applic laboratori
privileg host investor meet
execut director ir shawn bevec despit rate cut pama estim
drag view quest under-appreci larg cap cash cow well
posit consolid lab particularli hospit lab market
appear present competit edg lh view
contract repres possibl near-term posit catalyst fate
contract exclus labcorp set expir end
topic came recent investor meet remain
diagnost tool
activ dialogu execut optum unit well execut
highest level lh may renew exclus deal sens
grow likelihood exclus lab contract lh open
lh well believ stock correctli price
possibl outcom lack visibl specif impact expect street
volume/rev estim rise play similar estim
lh beyond declin scenario play quest point
meet present larg book busi unit out-
of-network bottom line still believ fairli meaning beneficiari
open contract includ lh particularli volum
clear open contract would benefit dgx revenue/requisit
believ would benefit volum revenu
lh flip flop aet contract think
possibl indic contract aet contract multipl
year believ unlik aet contract flip-flop
larg lab provid least time think like outcom
aet contract open lab lab negoti renew
respect larg health plan
anyth good come pama believ ye
wall street shot ask question later pama see silver line
negoti price increas two major commerci payor previous
price weight median feel good plan
expect rate cut alreadi low-cost lab provid feel good
 pipelin like expand larg number lab feel actual pinch
rate cut realiz put sale prudent believ
lab better posit consolid market target cash
flow op expect acceler asset purchas particularli
lab feel sting reimburs cut
acla lawsuit impact pama cut quest deriv total
rev clinic lab fee schedul clf quest
estim cut clf pama expect
cut rise relat on-going lawsuit
acla vs hh cautious optimist may see inclus hospit
outreach lab rate weight median formula next data collect
period happen could provid relief quest well lh
year reimburs revenue/requisit revenu
chang expect base case statu quo hold believ
stock price statu quo bottom line think chang statu quo
lawsuit might propel stock lh rise market
would assign higher multipl stock multi-year materi
major reimburs overhang stock view
dividend tax reform recent rais dividend
yield also major winner us tax reform target
tax rate result estim
save save expect drop
sharehold re-invest employe
busi primarili refresh number patient servic
center launch advanc esoter test present make
billion revenu higher profit mix hire genet
counselor quest reinvest larg focus technolog improv
enhanc user experi consum initi drive stronger organ
volum new higher valu esoter test save tax
diagnost tool
reform earmark award non-bonu elig employe receiv
bonu expect deploy back busi
growth help remind earn
call initi strong revenu guid y/i
adj ep
remind complet acquisit ad point
revenu growth guid assum point growth
much growth contribut growth
far earn accret goe acquir lab ie hospit outreach lab
indic busi acquir oper high singl digit
oper margin time move busi close mid
high teen level oper margin
quest long-term revenu financi target investor meet
reiter expect grow top line mid-
 organ growth new partnership hospit health
plan improv health plan access get back network
return high-singl digit growth esoter test current grow mid-singl
digit consum initi safeway myquest mobil app ancestri
etc also expect continu drive cost busi
save persist beyond dgx invigor program
achiev cost save year-end expect cost
save beyond believ best class compani shave
costs/year would impli specif
quantifi cost reduct target beyond think good amount
wood chop sever year compani continu improv lot
process materi chang year despit great technolog
advanc outsid lab industri includ addit consolid
system well facil requisit process today done
platform e-en autom effort continu execut exist
cost save initi reduc million annual bad debt
minut per patient reduc time per patient minut would
move needl
today requisit come via electron order indic
paper requisit cost electron order natur
expect grow order come electron state
particular goal time-frame
mobil side dgx myquest mobil app allow custom book
appoint check electron link payment option myquest
use nearli user increas user
hospit outreach lab remain plenti market favor target
quest priorit market share gain hospit much larger pie tune
market refer lab constitut
revenu market within hospit pie hospit outreach
busi amount entir lab market quest outreach
strategi involv purchas hospit outreach lab sign profession
laboratori servic pl agreement provid refenc lab test hospit
hospit continu staff lab believ hospit
system mani less sophist lh like havent
diagnost tool
quantifi yet felt impact pama impact begin sink
expect hospit system either approach will
despit leadership posit billion refer lab market
overal us lab pie given success traction partner
hospit pie acquir hospit outreach believ
earli day hospit strategi
figur believ pama tax reform posit target smaller less-sophist lab
figur target hospit outreach lab opportun profession lab servic agreement
diagnost tool
consum lh make larger invest better engag directli
consum frankli make sens compani like bid
similar contract oper safeway store near initi goal
expect hit expect continu expand retail
presenc safeway store next sever year addit quest open
locat store expect number increas though
dont visibl mani myquest mobil applic
use peopl y/i still small
take step get closer consum
quest patient servic center psc retail locat like
safeway psc locat strip mall offic build
safeway origin carv retail space therano abl
swoop therano oust psc staf
phlebotomist good candid move retail locat roughli
dgx test volum come patient servic center vs clinician
indic pay slightli less rent retail locat psc
expens attribut labor
data technolog enabl benefit consum
increasingli focus popul health name enabl health plan
provid better assess popul close gap care focu
connect patient phone home retail store conveni
set announc earli februari complet acquisit mobil
medic examin servic medxm provid home-bas health risk
assess relat servic hold substanti valu roughli
billion lab test data point system expect time look seek
monet data greater way
diagnost tool
benefit rise trend consum genet test ye
contract access overflow test consum genom test leader
ancestri dna expect grow nice beyond next-gener
sequenc leader indic consum genotyp
test perform nearli increas know
ancestri sold test kit black friday cyber monday alon
estim ancestri sold million test kit sinc
launch estim ancestri achiev custom end
estim direct-to-consum dtc test achiev driven
increas ancestri well upstart helix among other
new lab futur come clifton nj cost save like
quest break ground new lab clifton new jersey larger
marlborough lab futur current largest autom lab
world understand quest plan tear older teterboro nj lab
replac larger version marlborough lab wherea quest use
exist build marlborough lab expect build teterboro lab
ground provid estim cost build lab
expect multi-year project provid capital-expenditure guid
expect like achiev cost synergi consolid
real estat footprint quantifi target yet
collabor quintil squar solut optum perform well
quest quintil sign jv aim help biopharma custom bring
new drug therapi market support precis medicin quintil own
largest custom quest go win new busi quest
success maintain key custom servic sub-scal clinic trial
said believ fair say quintil jv rel small scope
quest nearli year revenu manag collabor optum
subsidiari unitedcar quest seen improv cash
collect reduct percentag denial histor
low double-digit quest abl lower even partner
optum optum enabl sync payor mirror server
help adjud claim current collabor servic six health plan
quest/optum intend add addit plan quest bad debt
expens histor hover around
expand capabl come
quest announc earli februari partnership offer
compani ngs-base oncomin dx target test companion diagnost panel
non-smal cell lung cancer quest partnership earn earli access
thermo pipelin novel platform assay assist develop
oncomine-brand solut clinic biopharma applic dgx
custom express interest target sequenc nipt test tumor
sequenc hereditari cancer test
cvs/aetna merger noth sweat dgx perspect
quest indic investor meet cvs/aetna merger impact
dgx agreement aet manag believ cvs/aet deal affirm dgx
retail strategi move closer patient recal oper patient servic
center safeway store earli jv store today
diagnost tool
earth shatter thesi chang labcorp deliv analyst day
solid case demonstr differenti leader major low-cost high
qualiti innov lab leader drug develop companion diagnost
increasingli capabl player consum test technolog lh remain one
compani univers trade discount multipl believ
may expand lh execut strategi stabil cro
busi drop save tax-reform reiter lh one
top pick pt adj ep
new consum blood self-collect devic analyst day labcorp quietli
announc launch new blood collect devic allow
consum self-collect blood specimen conveni home
turn around result day specimen land lab indic
us alreadi live at-hom collect devic mitra microsampl
devic blueprint athlet offer look expand broadli
consum focu store lh indic patient come
lh/walgreen clinic new custom lh earli read lh reach
peopl retail lh survey data indic
consum vs doc indic involv decis
lh well posit penetr global lab drug develop
market lh size global tam includ us lab
market ou lab market outsourc d/drug develop
market revenu today lh penetr runway growth
end sight opinion
drug develop well posit big data patient enrol opportun
earli lh well posit leader drug develop covanc
support clinic trial companion diagnost
market patient notifi covanc clinic trial
despit fact lh serv peopl lab year huge opportun
contract pose risk labcorp analyst day provid
updat unitedhealthcar contract view risk lh stock
lh well substanti dialogu unit lh
state expect contract updat rel short time-frame seem like
reason possibl open contact includ pose risk
lh volum howev think could partial off-set aet open
contract includ lh expect price war think may
come net winner rel lh test volum
growth outlook lh provid multi-year growth outlook analyst day like
accustom see other provid analyst day modest
disappoint lh affirm outlook mid-singl digit revenu grower
mid-to-upp singl digit drug develop low-to-mid singl digit core
diagnost bottom line lh track double-digit ep growth
move part pama aet contract
believ lh well posit drive mid-singl digit revenu least low
double-digit adj ep growth time complement acquisit oper
improv tax reform capit deploy
consum cant watch tv anymor without see ad either direct-to-
consum test ancestri com precis medicin opdivo
keytruda lh benefit remind lh refer laboratori
drug develop work import player
clinic trial design groundbreak therapi precis medicin
diagnost tool
topic consum test lh remain focus patient consum given
consum take greater respons well healthcar
rise co-pay deduct advanc technolog drive
expect conveni lh perform test consum per week
see consum per weekday person lh look deliv even
conveni flexibl test option price transpar improv access
engag patient beyond alreadi today consum
engag method includ automat remind servic confirm call
back text lh ran person survey determin involv decis
get lab test respond indic doctor
said said employ said famili member/friend
believ infanc consum genom test world-wide
figur lh ran person studi determin involv decis get lab test respond indic
doctor said said employ said famili member/friend
lh oper patient servic center retail locat employ
in-offic phlebotomist earli result collect lh show roughli
patient walgreen psc new labcorp vs compar non-
walgreen psc lh run walgreen site offer drive
consum satisfact includ labcorp precheck on-line reserv
labcorp express streamlin patient check-in patient out-of-pocket cost
estim provid custom cost estim individu health plan
labcorp patient provid access lab result invoic patient
recruit lh continu focu genet offer larg driven
consum age popul lh consid genet test market
opportun lh indic net promot score stand
view outstand demand price transpar consum set lh
expect valu proposit reson
diagnost tool
expect pama result lh consolid market labcorp
indic exclud pama price rel stabl lh remain
commit price disciplin intend let manag care organ
use pama negoti tactic lower price lh diagnost ceo gari huff
indic analyst day demand diagnost servic remain strong
serv overcom price constraint pama given magnitud pama
cut year alreadi paper-thin margin smaller lab expect
lh remain activ identifi acquisit target partnership opportun
regard acla lawsuit lh indic analyst day acla lawsuit
could decid june labcorp adj ep guidanc
contempl impact pama estim price reduct
diagnost segment off-set benefit tax reform
benefit continu oper perform
evalu possibl labcorp leverag region svp
control identifi potenti lead opportun pass level
manag decis render lh process evalu
opportun best character decentr funnel process mani
differ touch point flow central decision-mak process lh ceo
dave king covanc ceo john ratliff lh diagnost ceo gari huff lh look
deal accret earn cash flow year return greater
cost capit year three mani smaller integr lab lh
acquir met criteria end year one think impress
capit deploy lh deploy capit
includ covanc acquisit includ chiltern
share repurchas capital-expenditure lh continu invest heavili
capital-expenditure follow facil lab/oper
capital-expenditure invest support futur growth includ
expand capac autom collabor patient servic
center walgreen store genom immunotoxicolog capabl drug
develop expand capac raritan nj region laboratori medic drug
monitor shanghai drug develop facil invest
launchpad initi technolog autom
lh high-qual global leader penetr global lab
drug develop market lh size global tam includ
us lab market ou lab market outsourc d/drug
develop market revenu today lh penetr today
runway growth end sight
figur lh remain small fish rel global penetr market
diagnost tool
covanc lh spoke length analyst day leadership drug
develop covanc support clinic trial
companion diagnost market patient notifi
covanc clinic trial despit fact lh serv peopl lab
year huge opportun covanc increas backlog last
year expect drive y/i revenue growth includ mid-to-
high single-digit organ growth improv margin next year lh
indic ad new execut employe intern larg
attribut chiltern chiltern give lh immedi presenc emerg
biotech space add exposur women health ophthalmolog segment
covanc support clinic trial patient request
notifi covanc relev clinic studi covanc collabor
client companion diagnost cdx project cdx-
relat net-ord grew
lh note analyst day launchpad cost save initi shift
restructur process improv like portend margin expans
view lh realiz launchpad save expect addit
end achiev cost synergi relat
acquisit covanc
figur covanc offer ivd pathway singl pathway sspma cdx develop
diagnost tool
diagnost lh diagnost gener revenu revenu
compound-annual-growth-rate hold manag care contract lh diagnost includ
courier digit interfac servic popul lh
region laboratori offer test add roughli new test everi
year lh databas lab result interfac li vendor
goal diagnost segment includ drive profit growth
optim opportun larg form margin success acquisit
integr bad debt improv expans retail walgreen program
lh shi invest next-gener sequenc lh indic
invest significantli capabl specif north carolina
california lab call omniseq partnership molecular profil
oncolog key area focu improv autom includ lh robot
propel specimen process machin reduc specimen reject rate
lh consid genet test market peg medic drug
monitor women health market opportun
focu precis medicin person medicin top fda approv
first time covanc support fda approv
companion diagnost market includ approv kra egfr
braf specif project lh involv includ
thermo fisher oncomin dx test roch coba egfr vs plasma test
valid launch nivolumab pembrolizumab nsclc
driver includ genom proteom biomark base therapi
diagnost continu interest companion diagnost lh combin
diagnost tool
covanc diagnost capabl uniqu offer capabl span
biomark discoveri way commerci lh experi
ivd medic devic studi
covanc offer ivd pathway singl site pathway sspma custom
pursu companion diagnost solut current project split ivd
partnership pathway sspma pathway grow interest sspma
approach lh indic custom prefer two-way partnership sspma
approach vs tradit three-way partnership ivd pathway includ
pharma compani ivd cro revenu covanc cdx relat net-ord
grown cdx relat
backlog grown
figur lh offer custom tradit three-way cdx partnership two-way singl site pathway sspma pathway
covanc offer suit differenti drug develop tool clinic trial
plan execut includ pharmacu endpoint xceller global
pharmacu enabl pharma compani run trial effici metric
benchmark trial forecast
schedul improv visibl
xceller clinic data hub use clinic trial process extract data
present insight trial oper
global specimen solut network allow data flow freeli
multipl entiti uniqu investig follow differ protocol
leverag xceller databas identifi secur highest perform
investig indic one present case studi investig enrol
patient per site per month help xceller
figur lh provid updat financi target analyst day spoke balanc sheet capit structur target
diagnost tool
figur lh reiter guidanc analyst day
figur trade consensu adj ep well recent level lh trade street adj ep
diagnost tool
figur trade consensu revenu estim lh trade consensu revenu estim
diagnost tool
diagnost tool
canaccord genuiti estim compani report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
